{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'of hearing impairment is considered doubtful, it may be reasonable to avoid ototoxic drugs while', 'receiving teprotumumab, if possible.', 'Table 7.3', 'Summary of SAEs Reported in Either Treatment Group by Preferred Term', 'Placebo', 'Teprotumumab', 'N=44', 'N=43', 'Summary Details for SAEs in', 'SAE', 'n (%)', 'n (%)', 'Teprotumumab Group', 'Any SAE', '1 (2.3)', '5 (11.6)', 'Optic neuropathy', '1 (2.3)', '0', 'Diarrhea', '0', '1 (2.3)', 'Severe diarrhea in one subject with 6-month', 'history of ulcerative colitis - hospitalized', 'IBD', '0', '1 (2.3)', 'Subject with recent diagnosis of ileitis and colitis,', 'diagnosed and treated for IBD while on therapy -', 'hospitalized', 'Escherichia sepsis', '0', '1 (2.3)', 'E. coli infection of unknown origin, treated with', 'IV antibiotics - hospitalized', \"Suspected Hashimoto's\", '0', '1 (2.3)', 'Provisional diagnosis for episodic mental', 'encephalopathy', 'confusion with no other neurological symptoms -', 'hospitalized', 'Urinary retention', '0', '1 (2.3)', 'Occurred following an inguinal herniorrhaphy -', 'hospitalized', 'AEs Previously Identified as Special Interest', 'AESIs identified in the oncology studies (infusion-associated events, hyperglycemia,', 'thrombocytopenia, and anemia; see Section 7.1.3.4.5.5) were examined in TED01RV.', 'Infusion-associated AEs were reported for 1 teprotumumab-treated subject (facial flushing and', 'warmth with concomitant elevated heart rate and blood pressure at the end of the 90-minute', 'observation period after the second infusion). At the third infusion visit, the subject was pre-', 'medicated with diphenhydramine, dexamethasone, famotidine and Tylenol and had a similar', 'reaction prior to the study drug infusion.', 'Among non-diabetic subjects, hyperglycemia occurred at comparable rates in both treatment', 'groups and was uniformly Grade 1 and intermittent. Among diabetic subjects, Grade 2 or 3', 'hyperglycemia occurred in some teprotumumab-treated subjects; this was well-controlled after', 'diabetes medication adjustment. Glycemic control, as assessed by HbA1c, was at baseline levels', 'following the treatment phase for all subjects in the teprotumumab group.', 'No subjects experienced thrombocytopenia as an AE. There were small differences in the', 'population means of platelet values in the teprotumumab group compared to placebo that were', 'not considered clinically significant and, importantly, diminished with continued dosing.', 'No subjects experienced anemia as an AE.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 62 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '7.1.3.4.5.2 Safety Data Oncology Studies', 'In the oncology program, over 700 subjects were treated with teprotumumab. The safety profile', 'of teprotumumab in these studies was confounded by the poor health of the enrolled subjects', '(most had late-stage cancers) and the administration of combination therapy (teprotumumab in', 'conjunction with other cytotoxic agents) in some subjects. Safety data from the oncology studies', 'is summarized in the IB.', '7.1.3.4.5.3 Teprotumumab Material Safety Profile', '7.1.3.4.5.4 Sarcoma Monotherapy Study with Teprotumumab CHO Material', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 63 of 118']\n\n###\n\n", "completion": "END"}